Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6218278 | 0.91 | KDM4E (0.49) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL3603041 | 0.90 | PDK1 (0.48) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL19058584 | 0.85 | PDK2 (0.54) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL219552 | 0.84 | ALDH1A1 (0.59) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL979300 | 0.84 | PDK2 (0.53) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL5209585 | 0.82 | KDM4E (0.63) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL24842546 | 0.82 | KDM4E (0.55) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL5440723 | 0.82 | CA12 (0.56) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL1173751 | 0.81 | KDM4E (0.54) | KDM4EPDK1PDK2PDK3PDK4 | |
| SCHEMBL27953738 | 0.80 | KMT2A (0.63) | KDM4EPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803811-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2010-09-28 | — | — | US | disclosed |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | US | disclosed |
| US-7442708-B2 | 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-10-28 | — | — | US | disclosed |
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | SANOFI (FR) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203126-A1 | Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same | FGFR3, FGFR1, NTRK3 | KDM4E 3542/4885PDK1 2430/4885PDK2 1447/4885 |
| US-20090023770-A1 | Novel 1,2,3-Substituted Indolizine Derivatives, Inhibitors of FGFs, Method for Preparing Them and Pharmaceutical Compositions Containing Them | FGF2, FGF1, FGFR1 | KDM4E 2425/4885PDK1 2153/4885PDK2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.